Skip to content

US · APRE · BIOTECHNOLOGY

Aprea Therapeutics, Inc. (APRE) intrinsic value and stock valuation

$0.23as of 2026-11-21 · Mkt cap 4.03M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aprea Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values APRE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from APRE’s statements →

Aprea Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, PA 18902 aprea.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-12.6M
20172025
Free cash flow
-$-12.89M
20172025
Total equity
$12.4M-30.6% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$1.5M$580K$0.00$0.00
Operating income-$-13.23M-$-14.32M-$-15.47M-$-113.39M-$-37.45M
Net income-$-12.6M-$-12.96M-$-14.29M-$-112.66M-$-36.54M
EPSd-$-1.93M-$-2.35M-$-3.95M-$-1.41B-$-34.47M
Operating cash flow-$-12.89M-$-13.56M-$-12.18M-$-25.01M-$-37.69M
Capital expenditure$0.00-$-20K-$-90K$0.00$0.00
Free cash flow-$-12.89M-$-13.57M-$-12.27M-$-25.01M-$-37.69M
Total assets$15.9M$24M$22.7M$30.2M$56.8M
Total debt$0.00$0.00$0.00$0.00$190K
Net debt-$-14.6M-$-22.85M-$-21.61M-$-28.79M-$-52.89M
Total equity$12.4M$19.3M$18.3M$25.6M$49.5M
Cash and short-term investments$14.6M$22.9M$21.6M$28.8M$53.1M
Income statement
20252024202320222021
Revenue$0.00$1.5M$580K$0.00$0.00
Cost of revenue$0.00$9.36M$10K$16.4M$270K
Gross profit$0.00-$-7.86M$580K-$-16.4M-$-270K
Research and development expenses$7.04M$9.36M$7.63M$92.4M$23.9M
Selling, general and administrative expenses$6.48M$6.46M$8.42M$21M$13.6M
Other expenses-$-290K-$-9.36M$0.00-$-16.4M-$-270K
Operating expenses$13.2M$6.46M$16.1M$97M$37.2M
Cost and expenses$13.2M$15.8M$16.1M$113.4M$37.5M
Interest income$650K$1.29M$1.22M$450K$0.00
Interest expense$0.00$0.00$0.00$450K$0.00
Depreciation and amortization$20K$20K$10K$0.00$270K
Ebitda-$-12.58M-$-12.94M-$-14.28M-$-37.37M-$-36.86M
Operating income-$-13.23M-$-14.32M-$-15.47M-$-113.39M-$-37.45M
Total other income/expenses, net$630K$1.36M$1.19M$730K$320K
Income before tax-$-12.6M-$-12.96M-$-14.29M-$-112.66M-$-37.13M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-12.6M-$-12.96M-$-14.29M-$-112.66M-$-36.54M
Weighted average shares outstanding$6.54M$5.51M$3.62M$80K$1.06M
Weighted average diluted shares outstanding$6.54M$5.51M$3.62M$80K$1.06M
Balance sheet
20252024202320222021
Cash and short-term investments$14.6M$22.9M$21.6M$28.8M$53.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$15.6M$23.6M$22.5M$30.2M$56.6M
Property, plant and equipment, net$60K$80K$90K$0.00$210K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$40K$40K$0.00$0.00
Total non-current assets$370K$400K$130K$0.00$240K
Total assets$15.9M$24M$22.7M$30.2M$56.8M
Accounts payable$710K$1.35M$1.67M$840K$1.77M
Short-term debt$0.00$0.00$0.00$0.00$190K
Deferred revenue$0.00$0.00$530K$0.00$0.00
Total current liabilities$2.76M$3.36M$4.39M$3.2M$7.32M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$730K$1.31M$1.31M$1.31M$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$190K
Total liabilities$3.49M$4.67M$4.39M$4.51M$7.32M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-333.64M-$-321.04M-$-308.08M-$-293.8M-$-181.13M
Accumulated other comprehensive income (loss)-$-10.63M-$-10.63M-$-10.61M-$-10.62M-$-10.36M
Total equity$12.4M$19.3M$18.3M$25.6M$49.5M
Total investments$0.00$40K$40K$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$190K
Net debt-$-14.6M-$-22.85M-$-21.61M-$-28.79M-$-52.89M
Cash flow statement
20252024202320222021
Net income-$-12.6M-$-12.96M-$-14.29M-$-112.66M-$-37.13M
Depreciation and amortization$20K$20K$10K$190K$270K
Stock-based compensation$480K$490K$440K$17M$7.81M
Change in working capital-$-930K-$-1.06M$1.62M-$-1.76M-$-8.33M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-650K-$-310K$830K-$-860K-$-2.73M
Net cash provided by operating activities-$-12.89M-$-13.56M-$-12.18M-$-25.01M-$-37.69M
Investments in property, plant and equipment$0.00-$-20K-$-90K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-20K-$-90K$0.00$0.00
Common stock issued$4.64M$16.1M$5.79M$680K$1.54M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.64M$14.8M$5.14M$680K$1.75M
Net change in cash-$-8.25M$1.24M-$-7.14M-$-24.29M-$-35.94M
Cash at end of period$14.6M$22.9M$21.7M$28.8M$53.1M
Operating cash flow-$-12.89M-$-13.56M-$-12.18M-$-25.01M-$-37.69M
Capital expenditure$0.00-$-20K-$-90K$0.00$0.00
Free cash flow-$-12.89M-$-13.57M-$-12.27M-$-25.01M-$-37.69M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aprea Therapeutics, Inc.

        Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

        CEO
        Oren Gilad
        Employees
        8
        Beta
        1.56

        Explore

        Frequently asked questions

        What is the intrinsic value of Aprea Therapeutics, Inc. (APRE)?

        InvestorsCraft does not currently publish an intrinsic value for APRE. How the IC value is calculated.

        Is APRE undervalued?

        InvestorsCraft does not publish an undervaluation signal for APRE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.